Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Lescol XL

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Extended-release 80 mg tablet formulation of fluvastatin produced up to a 38% median decrease in low-density lipoprotein cholesterol in patients with dyslipidemia compared to Lescol 40 mg in Phase III clinical trials, the company said, announcing the Oct. 6 approval of the new tablet. "A 25% median decrease in triglycerides and a 13% mean increase in high-density lipoprotein cholesterol in patients with primary mixed dyslipidemia (Fredrickson Type IIb)" compared to Lescol 40 mg was also seen in the trials, the company reported. The NDA for the extended-release formulation was submitted Dec. 8, 199

You may also be interested in...

QUOTED. 28 September 2020. Kyle Sampson.

If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip

Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts